An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis

Neurosci Lett. 2009 May 15;455(2):120-3. doi: 10.1016/j.neulet.2009.02.048. Epub 2009 Feb 26.

Abstract

Methamphetamine continues to be the most widely abused drug in Japan. Chronic methamphetamine users show psychiatric signs, including methamphetamine psychosis. Monoamine oxidase A (MAOA) is one of the major enzymes responsible for the degradation of neurotransmitters. Abnormalities in MAO levels have been related to a wide range of psychiatric disorders. We examined whether or not the MAOA-u variable-number tandem repeat (VNTR) has a functional polymorphism in methamphetamine psychosis and whether or not such a polymorphism is related to the prolongation of psychosis. As expected, there was a significant difference in the MAOA-u VNTR between males with persistent versus transient methamphetamine psychosis (p=0.018, odds ratio (OR)=2.76, 95% CI: 1.18-6.46). Our results suggest that the high-activity allele class of MAOA-u VNTR in males may be involved in susceptibility to a persistent course of methamphetamine psychosis. We found no differences among females. The sample size of females with methamphetamine psychosis was too small to have significant analysis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Dopamine Agents / adverse effects*
  • Female
  • Gene Frequency
  • Genetic Predisposition to Disease*
  • Humans
  • Male
  • Methamphetamine / adverse effects*
  • Middle Aged
  • Monoamine Oxidase / genetics*
  • Polymorphism, Genetic
  • Psychoses, Substance-Induced / genetics*
  • Sex Factors
  • Substance-Related Disorders / complications
  • Young Adult

Substances

  • Dopamine Agents
  • Methamphetamine
  • Monoamine Oxidase